Catheter-directed intra-arterial thrombolysis: Size of soluble fibrin(ogen) degradation products studied by electrophoresis and immunoblotting

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 4, 1999, Pages 189-195

  Sandbæk, Gunnar ^a   Bjornsen S ^b   Brosstad, F ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NONE

Author keywords

Alteplase; Arterial occlusive disease; Electrophoresis; Fibrin; Fibrinogen degradation products; Immunoblotting; Infusions; Intra arterial; Molecular weight; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN DEGRADATION PRODUCT; HEPARIN;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ANGIOGRAPHY; ARTERY BYPASS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBOLISM; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVASCULAR CATHETER; MALE; MOLECULAR WEIGHT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUPERNATANT; THROMBUS; VENOUS BLOOD;

EID: 0032764304     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199906000-00005     Document Type: Article

References (7)

1. 1. Doolittle RF. Fibrinogen and fibrin [review]. Annu Rev Biochem 1984; 53: 195-229.
2. 2. Francis CW, Marder VJ. A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost 1982; 8: 25-35.
3. 3. Francis CW, Connaghan DG, Marder VJ. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation 1986; 74: 1027-1036.
4. 4. Clauss A. Gerinnungsphysiologische Schnellmetode zur Bestimmung ses Fibrinogens (a rapid method for determination of the fibrinogen concentration in plasma). Acta Haematologica 1957; 17: 237-246.
5. 5. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
6. 6. Gron B, Bennick A, Nieuwenhuizen W, Brosstad F. Normal and fibrinaemic patient plasma contain high-molecular weight crosslinked fibrin(ogen) derivatives with intact fibrinopeptide A. Thromb Res 1990; 57: 259-270.
7. 7. Seifried E, Tanswell P, Rijken DC, Kluft C, Hoegee E, Nieuwenhuizen W. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction [letter]. Lancet 1987; ii: 333-334.